Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 09:15am EDT

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2019 financial results after market close on Thursday, February 13, 2020. Management will hold a conference call to review the company's fourth quarter and full year 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the confirmation number "49260062" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
04/02DEXCOM SCHEDULES FIRST QUARTER 2020 : 30 p.m. Eastern Time
BU
03/30QUALCOMM : Names Heather Ace as Executive Vice President of Human Resources; Exe..
AQ
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
More news
Financials (USD)
Sales 2020 1 743 M
EBIT 2020 227 M
Net income 2020 162 M
Finance 2020 4,07 M
Yield 2020 -
P/E ratio 2020 149x
P/E ratio 2021 92,9x
EV / Sales2020 13,2x
EV / Sales2021 10,6x
Capitalization 22 964 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 282,74  $
Last Close Price 250,71  $
Spread / Highest target 31,6%
Spread / Average Target 12,8%
Spread / Lowest Target -26,2%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.14.62%22 964
MEDTRONIC PLC-16.74%126 592
BAXTER INTERNATIONAL INC.-1.33%41 850
HOYA CORPORATION3.79%33 246
TERUMO CORPORATION1.44%25 446
ZIMMER BIOMET HOLDINGS-31.91%21 063